{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:21:59Z","timestamp":1793841719094,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017787","name":"Health Science Center, University of North Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.chest.2021.03.070","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T17:54:30Z","timestamp":1618854870000},"page":"831-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease"],"prefix":"10.1016","volume":"160","author":[{"given":"David E.","family":"Griffith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Aksamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen J.","family":"Addrizzo-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Hoefsloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayton W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ciesielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard J.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Brown-Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2021.03.070_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccm.2014.10.003","article-title":"Environmental sources of nontuberculous mycobacteria","volume":"36","author":"Falkinham","year":"2015","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.chest.2021.03.070_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.chest.2021.03.070_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2021.03.070_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium complex pulmonary disease","volume":"82","author":"Kwon","year":"2019","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"2","key":"10.1016\/j.chest.2021.03.070_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4046\/trd.2016.79.2.74","article-title":"Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians\u2019 perspectives","volume":"79","author":"Ryu","year":"2016","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"4","key":"10.1016\/j.chest.2021.03.070_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDS clinical practice guideline: executive summary","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.chest.2021.03.070_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","article-title":"Therapy of refractory nontuberculous mycobacterial lung disease","volume":"25","author":"Griffith","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"10.1016\/j.chest.2021.03.070_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.03.070_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2021.03.070_bib10","first-page":"210","article-title":"Nontuberculous mycobacterial pulmonary infections","volume":"6","author":"Johnson","year":"2014","journal-title":"J\u00a0Thorac Dis"},{"issue":"3","key":"10.1016\/j.chest.2021.03.070_bib11","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.03.070_bib12","first-page":"27","article-title":"Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.chest.2021.03.070_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.03.070_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in\u00a0vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.chest.2021.03.070_bib15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.chest.2021.03.070_bib16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.03.070_bib17","doi-asserted-by":"crossref","unstructured":"Griffith DE, Thomson R, Addrizzo-Harris DJ, et\u00a0al. Durability of culture conversion in patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LS) in the CONVERT study. Paper presented at: European Respiratory Society Meeting; September 28-October 2, 2019; Madrid, Spain. Abstract oa4951.","DOI":"10.1183\/13993003.congress-2019.OA4951"},{"issue":"4","key":"10.1016\/j.chest.2021.03.070_bib18","doi-asserted-by":"crossref","first-page":"109A","DOI":"10.1016\/j.chest.2018.08.095","article-title":"Relationship between in\u00a0vitro clarithromycin susceptibility and sputum culture conversion with add-on amikacin liposome inhalation suspension (ALIS) for treatment of refractory Mycobacterium avium complex (MAC) lung disease [abstract]","volume":"154","author":"Griffith","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.03.070_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2021.03.070_bib21","first-page":"45","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J\u00a0Postgrad Med"},{"issue":"2","key":"10.1016\/j.chest.2021.03.070_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/341207","article-title":"Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis","volume":"186","author":"Wallace","year":"2002","journal-title":"J\u00a0Infect Dis"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221007030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221007030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:59:54Z","timestamp":1762124394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221007030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0012369221007030"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.03.070","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.03.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}